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α-synuclein is a protein involved in the pathogenesis of several so-called synucleinopathies including Parkinson’s disease. A variety
of models have been so far assessed. Human induced pluripotent stem cells provide a patient- and disease-speciﬁc model for in
vitro studies, pharmacotoxicological screens, and hope for future cell-based therapies. Initial experimental procedures include the
harvest of patients’ material for the reprogramming process, the investigation of the patients genetic background in the cultured
cells, and the evaluation of disease-relevant factors/proteins under various cell culture conditions.
1. α-SynucleinandParkinson’s Disease
α-synuclein is a protein that is believed to interact with
presynaptic vesicles and to be involved in the regulation of
dopamine transport, secretion, and reuptake [1], possibly
by interacting with the SNARE complex [2]. In addition,
it is believed to have additional nuclear and cytoplasmic
functions. However it gained its prominence through its
role in the pathology of Parkinson’s disease (PD) and
several other neurodegenerative diseases summarized as
synucleinopathies [3]. α-synuclein can form ﬁbrils and
α-synuclein containing aggregates, so-called Lewy bodies
and Lewy dendrites which are major characteristics of PD
neuropathology. Their involvement in PD occurrence and
neurodegeneration has not yet been ﬁnally unraveled. The
discovery of α-synuclein overexpressing or point mutations
in some PD patients, which have a higher tendency to form
ﬁbrils, additionally strengthened the belief that this protein
has one of the central roles in PD [4]. Several in vitro
and in vivo models have therefore been established to study
the formation of ﬁbrils, Lewy Bodies, and the mechanism
of neurodegeneration [5]. Interestingly, the high tendency
to form ﬁbrils seems to be characteristic for the human
protein. While mice overexpressing mouse α-synuclein had
no neural phenotype, mice overexpressing the human α-
synuclein suﬀered from neurodegeneration [6]. This showed
that although protein function and interactions as well as
pathologic mechanisms could be partly analyzed in animals
and cultured animal cells, all these ﬁndings have to be
carefully checked in a human system which is as close to
the real disease pathology as possible. In addition, the use
of human cells could even reveal additional mechanistical
ﬁndings that could not be mimicked in rodents.
2.DiseaseModels inSynucleopathies
Basically, disease modeling is performed in several branches.
In brief, In vivo studies include primarily patient’s clinical
features associated with disease morphology and progress
[7, 8]. Clinical studies for PD include the evaluation
of, for example, radiological changes (organ morphology,
transmitter release/uptake, signs of degeneration such as
plaques or metabolic dysfunction), symptom rating, disease
course, or pharmacotoxicological trials. Secondly, genetic
investigationssearchingfordiseaserelevantgeneabberations
and familiar cosegregation are of great value for the under-
standing and treatment of such degenerative syndromes.
Additionally, in vivo modeling includes several animal mod-
els starting from lower animals such as the worm C. elegans,
the ﬂy D. melanogaster or the Zebraﬁsh D. rerio [9, 10].
These kinds of animal models not only provide systematic
insights into genetic disease background but also help to2 Stem Cells International
elucidate pathways in pathogenesis. Apart from that, they
allow a relatively easy to handle model at low costs. Still,
diseases like PD also involve studies using higher animals
up to models mimicking the human organism, namely,
monkeys and apes. Certainly, most higher animal models
consist of mice models in various compositions [5]. These
mice can nowadays be generated relatively easy with valuable
features such as genetic knock down or even organ speciﬁc
and/or in an inducible manner. These models are utilized
for a variety of studies. Mouse models in general stand
for investigations of, for example, the pathomechanisms,
diseaseprogression,genefunction,orpharmacotoxicological
evaluations. On the other hand, in vitro studies often make
use of cellular setups. Of high interest for PD studies
are cell cultures consisting of dopaminergic neurons from
diﬀerent sources. Until recently, most of these cell models
were harvested from rodents or other animals. Investigations
on these models carry the advantage of broad access to
detailed cellular mechanisms. Genetic modulation of single
cellsadditionallyprovideinsightsintocellularprocessessuch
as diﬀerentiation, migration, and function or degenerating
processes such as apoptosis or necrosis. Especially, stem cells
are used for studies of diﬀerentiation and maturation. In PD
several diﬀerent sources and types of stem cells are used.
The following exemplary diﬀerences exist: (i) pluripotent
embryonic stem (ES) cells are a good source for dopamin-
ergic neurons and may be used for future cell therapeutic
approaches and as platforms for pharmacotoxicological
assays. Still, they inherit ethical and legal prohibitions and
harbor certain dangers such as teratoma formation in vivo.
(ii) Neural stem cells (adult stem cells) provide a source
for even autologous dopaminergic neurons and can be used
forpatient-speciﬁcanddisease-speciﬁcpathogenicinvestiga-
tions [11–15]. Nevertheless, these cells are extremely diﬃcult
to harvest, and this is only possible by harmful surgical
intervention. Additionally, (up to now) these cells cannot be
passaged over a long time and lose their potential to generate
dopaminergic neurons over time. (iii) Mesenchymal stem
cells from the bone marrow are thought to be amongst the
most easy to harvest individual stem cell sources. These cells
are also thought to be a certain source for dopaminergic
neurons and provide a good hope for future cell-based
therapies for a variety of neurodegenerative disorders [16].
But,theeﬃciencyofdopaminergicdiﬀerentiationisverylow
and research is still far away from a cell-based therapy.
3. Induced Pluripotent Stem Cells as
aDisease Model
Studying neurodegenerative diseases in human cells is of
course a diﬃcult task. Since the aﬀected cells cannot be
propagated in culture and the supply of primary material is
very limited, they cannot be widely used as a model system.
As depicted in the last paragraph the use of ES cells and
the subsequent diﬀerentiation into neural stem cells and
neurons could partially circumvent this barrier. However
their use is discussed very controversially in several countries
due to ethical concerns. This issue has been resolved by
the discovery of induced pluripotent stem cells (iPS cells).
iPS cells are produced from somatic cells like ﬁbroblasts
or keratinocytes and can be reprogrammed by the forced
overexpression of certain transcription factors (known as the
Yamanaka factors Oct4, Sox2, Klf4, c-Myc (OSKM)) into
a state that strongly resembles embryonic stem cells [17].
These cells can subsequently be subjected to diﬀerentiation
into virtually all cells of the organism [18]a n do fc o u r s e
to neural diﬀerentiation (as depicted in Section 4 in more
detail) (Figure 1(a)), especially into dopaminergic neurons
whicharemostaﬀectedbyPD[19].Thismethodcouldprove
even more valuable by the use of cells from PD patients with
α-synuclein mutations to evaluate and compare their iPS
cell-derived neurons with healthy ones. By these means it is
possible to verify ﬁndings from animal cell culture systems
and other in vitro assays in human cells very similar or
even identical to the ones which are actually aﬀected in PD
patients.Thereforeitisofimportancetoestablishavarietyof
iPS cell lines from diﬀerent donors with α-synuclein-related
diseases.
4. Generation and Differentiation of
Patient-SpeciﬁciPSCells
The ﬁrst question when reprogramming somatic cells into
iPS cells is that of the cell type being reprogrammed.
Traditionally, most groups used ﬁbroblasts from punch
biopsies since they are relatively easy to get and to propagate.
However, when planning to generate patient-speciﬁc cell
lines one has to consider that the acceptance to perform a
punch biopsy is not very high since it is still an invasive and
painful process. Therefore we favor the use of keratinocytes
frompluckedscalphairasastartingcellsource(Figure 1(b)).
These cells can be obtained by noninvasive means and,
in addition, have a much higher reprogramming eﬃciency
compared to skin ﬁbroblasts [18, 20]. Recent ﬁndings indi-
cating that rediﬀerentiating iPS cells favor cell types close to
their origin before reprogramming reinforce the beneﬁts of
keratinocytes as starting cells since they are of ectodermal
origin and closer related to neurons than ﬁbroblasts [21].
The delivery of the four reprogramming factors Oct4,
Sox2, Klf4 and c-Myc is preferably done via lentiviral trans-
fectionofapolycistronicandexcisableconstruct.Thissystem
still harbors the highest eﬃciencies [22, 23]. Although there
were several other methods described, including transient
transfection or protein transduction [24, 25], these have very
low eﬃciencies and are not well usable for the generation
of patient-speciﬁc cell lines. The transfection of modiﬁed
RNAs was described as very eﬃcient for reprogramming but
has still to be evaluated on a broader basis [26]. Lentiviral
transfectionofcoursehasthenegativeeﬀectofrandomDNA
integrationintothegenome.Thiscanpartiallybediminished
by using cre-excisable lentiviral constructs. However, in
order to minimize side eﬀects caused by the integration as
well as the variances between diﬀerent lines it is important to
evaluate a certain number of lines, preferably from diﬀerent
donors.
When producing patient-speciﬁc iPS cells it is important
to have high reprogramming eﬃciencies, since the patient
material is limited. Therefore the use of high-quality culturesStem Cells International 3
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Figure 1: Production of iPS cell-derived neurons follows basic developmental steps. (a) Keratinocytes are reprogrammed into iPS cells by
forced overexpression of the Yamanaka factors (OSKM). After diﬀerentiation into ectodermal cells neural stem cells can be isolated from the
centers of the forming neural rosettes. These neural stem cells can be subsequently diﬀerentiated into neurons, (b) proliferating keratinocyte
culture, (c) iPS cell colony in a feeder-free culture, (d) neural rosette shortly before dissection and isolation of neural stem cells, (e) adherent
culture of neural stem cells, and (f) iPS cell-derived neurons after four weeks of culture.
of the reprogrammed cells as well as the feeder cells used
in the reprogramming process is crucial. In addition several
selection methods have been described to ease the isolation
of true iPS cells [27, 28]. The arising iPS cells have to be
thoroughlycharacterizedtoensuretheirtrueiPS cellidentity
(Figure 1(c)).
The diﬀerentiation of iPS cells into neurons has already
been extensively studied with ES cells [29, 30]. Available
protocols, although greatly varying in detail, share some
general steps. Typically, diﬀerentiation of iPS cells is started
by withdrawal of FGF2. In suspension culture this is used
to form embryoid bodies containing precursor cells of all
lineages. The diﬀerentiation into the ectodermal and neu-
roectodermal lineage can, however, be highly enhanced by
addition of the BMP antagonist Noggin (as well as the small
molecule dorsomorphin) and even more in combination
with SB431542, a TGFβ pathway inhibitor [31, 32]. Together
thesetwosubstancescaninducestrongneuraldiﬀerentiation
even under adherent conditions and in lines with a low
neural diﬀerentiation potential. Under adherent conditions
cells start to form neural rosettes (Figure 1(d)). They consist
of PAX6 or Nestin-positive neural stem cells (NSCs) and
mimic the development of the neural tube in vitro.T o
exclude undiﬀerentiated cells or cells diﬀerentiating into a
diﬀerent fate the inner regions of the neural rosettes can
be mechanically or enzymatically detached. This ensures a
high purity and a similar diﬀerentiation stage of the NSCs.
NSCs can be cultured under adherent conditions or in
suspension as neurospheres (Figure 1(e)). However, it is not
clear for how long these cells can be cultured without a
reduction or change in their diﬀerentiation potential. Dif-
ferent culture conditions for NSCs and thereafter of the
arising neurons have been reported to favor the generation
of certain neuronal subtypes, like glutamatergic neurons,
dopaminergic neurons, or motor neurons (Figure 1(f))[ 30,
33]. To induce ﬁnal diﬀerentiation cells are treated with a
mixture neurotrophic factors like the brain-derived or the
glial-derived neurotrophic factor (BDNF and GDNF) as well
as region-speciﬁc morphogens like Sonic hedgehog. High
reproducibility in cell survival, culture quality and synapse
formation has been reported for cocultures with glial cells
[34]. These could be of mouse or human origin but also
generated themselves from patient-speciﬁc iPS cells [35]. Of
course this could be of relevance especially for diseases where
glial cells cause or contribute to the pathologic eﬀects.
5.PerspectivesiniPSCell-Based
Synucleinopathy Research
The aim of upcoming iPS cell-based studies would be to
study the morphology and electrophysiological behavior of
synucleinopathy-derived neurons and compare them with
healthy cells. Since α-synuclein is especially involved in the
synaptic compartment, alterations there would be of great
interest[2].ItwasalreadyshownthatiPScell-derivedhuman
neurons express α-synuclein [36]. The ﬁrst synuclein-related
patient iPS cell line-derived neurons with a triplication
of the α-synuclein (SNCA) gene show a higher amount
of α-synuclein protein compared to healthy control cells
[37]. In addition to the already published relatively young
neurons, we could show α-synuclein in immunostainings of
mature iPS cell-derived neurons with a nuclear as well as
vesicular staining pattern (Figure 2(a)). They also express
the gene at a higher rate compared to iPS cells or NSCs
(Figure 2(b)). Interestingly, the gene LRRK2 (leucine-rich
repeat kinase 2) is also upregulated in diﬀerentiated neurons
(Figure 2(c)). This PD-associated gene was described to
enhance the ability of α-synuclein to form aggregates [38].4 Stem Cells International
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Figure 2: iPS cell-derived neurons express α-synuclein. (a) Immunoﬂuorescence stainings of α-synuclein in TH (tyrosine hydroxylase) and
TUBB3 (Tubulin beta-III) positive dopaminergic neurons after 5 months of diﬀerentiation show nuclear and vesicular localisation of α-
synuclein, (b) and (c) RNA expression of α-synuclein (SNCA) and leucine-rich repeat kinase 2 (LRRK2) is upregulated in neurons compared
toiPScellsandneuralstemcells(NSCs)(normalizedtothehouse-keepinggeneHMBS),and(d)SubcellularfractionationofiPScell-derived
neurons shows nuclear (P1 fraction) and membrane associated, likely synaptic localization (P2 fraction) of α-synuclein.Stem Cells International 5
Neurons derived from patient iPS cells with a LRRK2
mutation show enhanced stress sensitivity and an elevated
α-synuclein levels [39]. In a subcellular fractionation α-
synuclein is present in the nuclear fraction (P1) but mainly
in the P2 fraction containing membrane associated proteins
and the synaptic compartment (Figure 2(d)). Another very
intriguing study would be to evaluate ageing in these iPS
cell-derived neurons. For this they have to be kept in culture
for prolonged periods of time and/or additionally stressed to
provoke the formation of plaque-like structures in vitro. This
wouldbeaverypowerfultoolsinceitthenwouldrecapitulate
the neuronal changes observed in PD patients. If cultured
cells can be reliably provoked to form α-synuclein aggregates
and plaques they also would be an ideal readout system
for pharmaceutical research and evaluation of potential PD
drugs. Since solely human α-synuclein and its mutated
forms seem to have this high tendency to form plaques the
use of iPS cell-derived human neurons can be crucial to
evaluate the exact pathomechanisms involved in formation
of synucleinopathies. The ﬁnal step would be to recapitulate
the observed phenotypes of the patient-derived cells in
healthy cells where the genes of interest are artiﬁcially
modiﬁed. This method has already been demonstrated with
α-synuclein point mutations [40]. The additional use of
such isogenic controls with single alterations is important to
ﬁnally prove the monogenic disease potential of genes like α-
synucleinorLRRK2andruleoutadditionalbutyetunknown
mutations.
Conﬂict of Interests
The authors declare no potential conﬂicts of interest.
References
[1] A. Sidhu, C. Wersinger, and P. Vernier, “Does α-synuclein
modulate dopaminergic synaptic content and tone at the
synapse?” FASEB Journal, vol. 18, no. 6, pp. 637–647, 2004.
[2] J.Burr´ e,M.Sharma,T .T setsenis,V .Buchman,M.R.Ethert on,
a n dT .C .S ¨ udhof, “α-synuclein promotes SNARE-complex
assembly in vivo and in vitro,” Science, vol. 329, no. 5999, pp.
1663–1667, 2010.
[3] M. Goedert, “Alpha-synuclein and neurodegenerative dis-
eases,” Nature Reviews Neuroscience, vol. 2, no. 7, pp. 492–501,
2001.
[4] K. A. Conway, J. D. Harper, and P. T. Lansbury, “Accelerated in
vitro ﬁbril formation by a mutant α-synuclein linked to early-
onset Parkinson disease,” Nature Medicine, vol. 4, no. 11, pp.
1318–1320, 1998.
[5] M. F. Chesselet, “In vivo alpha-synuclein overexpression in
rodents: a useful model of Parkinson’s disease?” Experimental
Neurology, vol. 209, no. 1, pp. 22–27, 2008.
[6] S. Chandra, G. Gallardo, R. Fern´ andez-Chac´ on, O. M.
Schl¨ uter,andT.C.S¨ udhof,“α-synucleincooperateswithCSPα
in preventing neurodegeneration,” Cell, vol. 123, no. 3, pp.
383–396, 2005.
[7] H.Braak,D.R.Thal,andK.DelTredici,“Nervecellsimmuno-
reactive for p62 in select hypothalamic and brainstem nuclei
of controls and Parkinson’s disease cases,” Journal of Neural
Transmission, vol. 118, no. 5, pp. 809–819, 2011.
[ 8 ]N .K .F o c k e ,G .H e l m s ,P .M .P a n t e le ta l . ,“ D i ﬀerentiation of
typical and atypical Parkinson syndromes by quantitative MR
imaging,” American Journal of Neuroradiology, vol. 32, no. 11,
pp. 2087–2092, 2011.
[9] Z. Liu, S. Hamamichi, B. D. Lee et al., “Inhibitors of
LRRK2 kinase attenuate neurodegeneration and Parkinson-
like phenotypes in Caenorhabditis elegans and Drosophila
Parkinson’s disease models,” Human Molecular Genetics, vol.
20, no. 20, pp. 3933–3942, 2011.
[10] I. S. Pienaar, J. G¨ otz, and M. B. Feany, “Parkinson’s disease:
insights from non-traditional model organisms,” Progress in
Neurobiology, vol. 92, no. 4, pp. 558–571, 2010.
[11] A. Hermann, M. Maisel, F. Wegner et al., “Multipotent neural
stem cells from the adult tegmentum with dopaminergic
potential develop essential properties of functional neurons,”
Stem Cells, vol. 24, no. 4, pp. 949–964, 2006.
[12] S. Liebau, B. Vaida, C. Proepper et al., “Formation of cellular
projections in neural progenitor cells depends on SK3 channel
activity,” Journal of Neurochemistry, vol. 101, no. 5, pp. 1338–
1350, 2007.
[13] S. Liebau, B. Vaida, A. Storch, and T. M. Boeckers, “Matura-
tion of synaptic contacts in diﬀerentiating neural stem cells,”
Stem Cells, vol. 25, no. 7, pp. 1720–1729, 2007.
[14] S. Liebau, C. Pr¨ opper, T. B¨ ockers et al., “Selective blockage
of Kv1.3 and Kv3.1 channels increases neural progenitor cell
proliferation,” Journal of Neurochemistry,v o l .9 9 ,n o .2 ,p p .
426–437, 2006.
[15] A. Hermann, M. Maisel, S. Liebau et al., “Mesodermal cell
types induce neurogenesis from adult human hippocampal
progenitor cells,” Journal of Neurochemistry, vol. 98, no. 2, pp.
629–640, 2006.
[16] K.A.TrzaskaandP.Rameshwar,“Dopaminergicneuronaldif-
ferentiation protocol for human mesenchymal stem cells,”
Methods in Molecular Biology, vol. 698, pp. 295–303, 2011.
[17] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of
Pluripotent Stem Cells from Adult Human Fibroblasts by
Deﬁned Factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007.
[18] M. M¨ uller, S. Stockmann, D. Malan et al., “Ca2+-activated
K+ -Channels -new tools to induce cardiac commitment from
pluripotentstemcellsinmiceandmen,”StemCellReviewsand
Reports. In press.
[19] A. Swistowski, J. Peng, Q. Liu et al., “Eﬃcient generation
of functional dopaminergic neurons from human induced
pluripotent stem cells under deﬁned conditions,” Stem Cells,
vol. 28, no. 10, pp. 1893–1904, 2010.
[20] T. Aasen, A. Raya, M. J. Barrero et al., “Eﬃcient and rapid
generation of induced pluripotent stem cells from human
keratinocytes,” Nature Biotechnology, vol. 26, no. 11, pp. 1276–
1284, 2008.
[21] O. Bar-Nur, H. A. Russ, S. Efrat, and N. Benvenisty, “Epige-
netic memory and preferential lineage-speciﬁc diﬀerentiation
in induced pluripotent stem cells derived from human
pancreatic islet beta cells,” Cell Stem Cell, vol. 9, no. 1, pp. 17–
23, 2011.
[22] C. A. Sommer, A. G. Sommer, T. A. Longmire et al., “Excision
of reprogramming transgenes improves the diﬀerentiation
potential of iPS cells generated with a single excisable vector,”
Stem Cells, vol. 28, no. 1, pp. 64–74, 2010.
[23] C. A. Sommer, M. Stadtfeld, G. J. Murphy, K. Hochedlinger,
D.N.Kotton,andG.Mostoslavsky,“Inducedpluripotentstem
cellgenerationusingasinglelentiviralstemcellcassette,”Stem
Cells, vol. 27, no. 3, pp. 543–549, 2009.6 Stem Cells International
[24] Y. Junying, H. Kejin, S. O. Kim et al., “Human induced
pluripotent stem cells free of vector and transgene sequences,”
Science, vol. 324, no. 5928, pp. 797–801, 2009.
[25] H. Zhou, S. Wu, J. Y. Joo et al., “Generation of induced
pluripotent stem cells using recombinant proteins,” Cell Stem
Cell, vol. 4, no. 5, pp. 381–384, 2009.
[26] L. Warren, P. D. Manos, T. Ahfeldt et al., “Highly eﬃcient
reprogramming to pluripotency and directed diﬀerentiation
ofhumancellswithsyntheticmodiﬁedmRNA,”CellStemCell,
vol. 7, no. 5, pp. 618–630, 2010.
[27] A. Hotta, A. Y. L. Cheung, N. Farra et al., “Isolation of human
iPS cells using EOS lentiviral vectors to select for pluripoten-
cy,” Nature Methods, vol. 6, no. 5, pp. 370–376, 2009.
[28] B. Di Stefano, S. M. Maﬃoletti, B. Gentner et al., “A
microRNA-based system for selecting and maintaining the
pluripotent state in human induced pluripotent stem cells,”
Stem Cells, vol. 29, no. 11, pp. 1684–1695, 2011.
[ 2 9 ]S .C .Z h a n g ,M .W e r n i g ,I .D .D u n c a n ,O .B r ¨ ustle, and J.
A. Thomson, “In vitro diﬀerentiation of transplantable neu-
ral precursors from human embryonic stem cells,” Nature
Biotechnology, vol. 19, no. 12, pp. 1129–1133, 2001.
[30] P. Koch, T. Opitz, J. A. Steinbeck, J. Ladewig, and O. Br¨ ustle,
“A rosette-type, self-renewing human ES cell-derived neural
stem cell with potential for in vitro instruction and synaptic
integration,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 106, no. 9, pp. 3225–3230,
2009.
[31] A. Morizane, D. Doi, T. Kikuchi, K. Nishimura, and J.
Takahashi, “Small-molecule inhibitors of bone morphogenic
protein and activin/nodal signals promote highly eﬃcient
neural induction from human pluripotent stem cells,” Journal
of Neuroscience Research, vol. 89, no. 2, pp. 117–126, 2011.
[ 3 2 ] S .M .C h a m b e r s ,C .A .F a s a n o ,E .P .P a p a p e t r o u ,M .
Tomishima, M. Sadelain, and L. Studer, “Highly eﬃcient neu-
ral conversion of human ES and iPS cells by dual inhibition
of SMAD signaling,” Nature Biotechnology,v o l .2 7 ,n o .3 ,p p .
275–280, 2009.
[33] M. Stockmann, L. Linta, K. J. F¨ ohr et al., “Developmental and
functionalnatureofhumaniPSCderivedmotoneurons,” Stem
Cell Reviews and Reports. In press.
[34] K.J.Brennand,A.Simone,J.Jouetal.,“Modellingschizophre-
nia using human induced pluripotent stem cells,” Nature, vol.
473, no. 7346, pp. 221–225, 2011.
[35] R. Krencik, J. P. Weick, Y. Liu, Z.-J. Zhang, and S.-C.
Zhang, “Speciﬁcation of transplantable astroglial subtypes
fromhumanpluripotentstemcells,”NatureBiotechnology,vol.
29, no. 6, pp. 528–534, 2011.
[36] J. R. Mazzulli, Y.-H. Xu, Y. Sun et al., “Gaucher disease gluco-
cerebrosidaseandα-synucleinformabidirectionalpathogenic
loop in synucleinopathies,” Cell, vol. 146, no. 1, pp. 37–52,
2011.
[37] M. J. Devine, M. Ryten, P. Vodicka et al., “Parkinson’s disease
induced pluripotent stem cells with triplication of the α-
synuclein locus,” Nature Communications, vol. 2, no. 1, p. 440,
2011.
[38] K. Kondo, S. Obitsu, and R. Teshima, “α-Synuclein aggre-
gation and transmission are enhanced by leucine-rich repeat
kinase 2 in human neuroblastoma SH-SY5Y cells,” Biological
and Pharmaceutical Bulletin, vol. 34, no. 7, pp. 1078–1083,
2011.
[39] H. N. Nguyen, B. Byers, B. Cord et al., “LRRK2 mutant iPSC-
derived da neurons demonstrate increased susceptibility to
oxidative stress,” Cell Stem Cell, vol. 8, no. 3, pp. 267–280,
2011.
[40] F. Soldner, J. Lagani` ere, A. W. Cheng et al., “Generation of
isogenicpluripotentstemcellsdiﬀeringexclusivelyattwoearly
onset parkinson point mutations,” Cell, vol. 146, no. 2, pp.
318–331, 2011.